Compare ROMA & FTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ROMA | FTH |
|---|---|---|
| Founded | 2018 | 1999 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 520.6M | 507.8M |
| IPO Year | 2022 | 2021 |
| Metric | ROMA | FTH |
|---|---|---|
| Price | $5.51 | $7.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 15 |
| Target Price | N/A | ★ $56.15 |
| AVG Volume (30 Days) | 36.5K | ★ 679.1K |
| Earning Date | 12-22-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.16 | $8.54 |
| 52 Week High | $11.77 | $42.14 |
| Indicator | ROMA | FTH |
|---|---|---|
| Relative Strength Index (RSI) | 33.90 | 23.28 |
| Support Level | $4.54 | N/A |
| Resistance Level | $8.68 | $21.97 |
| Average True Range (ATR) | 0.43 | 1.77 |
| MACD | 0.04 | -0.45 |
| Stochastic Oscillator | 0.00 | 0.40 |
Roma Green Finance Ltd is a professional specialist in the provision of environmental, social and governance (ESG), sustainability and climate change related advisory services through its operating subsidiaries in Hong Kong and Singapore. Its services include Sustainability Program Development, ESG Reporting, Corporate Governance and Risk Management, Climate Change Strategies and Solutions, Environmental Audit, ESG Rating Support and Shareholder Communication, and Education and Training. It operates in one reporting business segment in Hong Kong and Singapore, of which the majority of revenue is derived from Hong Kong.
Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's principal program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer.